» Articles » PMID: 29325228

Effects of Trastuzumab and Afatinib on Kinase Activity in Gastric Cancer Cell Lines

Overview
Journal Mol Oncol
Date 2018 Jan 12
PMID 29325228
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular mechanism of action of the HER2-targeted antibody trastuzumab is only partially understood, and the direct effects of trastuzumab on the gastric cancer signaling network are unknown. In this study, we compared the molecular effect of trastuzumab and the HER kinase inhibitor afatinib on the receptor tyrosine kinase (RTK) network and the downstream-acting intracellular kinases in gastric cancer cell lines. The molecular effects of trastuzumab and afatinib on the phosphorylation of 49 RTKs and 43 intracellular kinase phosphorylation sites were investigated in three gastric cancer cell lines (NCI-N87, MKN1, and MKN7) using proteome profiling. To evaluate these effects, data were analyzed using mixed models and clustering. Moreover, proliferation assays were performed. Our comprehensive quantitative analysis of kinase activity in gastric cancer cell lines indicates that trastuzumab and afatinib selectively influenced the HER family RTKs. The effects of trastuzumab differed between cell lines, depending on the presence of activated HER2. The effects of trastuzumab monotherapy were not transduced to the intracellular kinase network. Afatinib alone or in combination with trastuzumab influenced HER kinases in all cell lines; that is, the effects of monotherapy and combination therapy were transduced to the intracellular kinase network. These results were confirmed by proliferation analysis. Additionally, the MET-amplified cell line Hs746T was identified as afatinib nonresponder. The dependence of the effect of trastuzumab on the presence of activated HER2 might explain the clinical nonresponse of some patients who are routinely tested for HER2 expression and gene amplification in the clinic but not for HER2 activation. The consistent effects of afatinib on HER RTKs and downstream kinase activation suggest that afatinib might be an effective candidate in the future treatment of patients with gastric cancer irrespective of the presence of activated HER2. However, MET amplification should be taken into account as potential resistance factor.

Citing Articles

Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.

He X, Chen X, Yang C, Wang W, Sun H, Wang J PeerJ. 2024; 12:e16951.

PMID: 38436027 PMC: 10909369. DOI: 10.7717/peerj.16951.


Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma.

Hu C, Pei S, Wang J, Zu L, Shen W, Yuan L Cancer Chemother Pharmacol. 2023; 92(5):341-355.

PMID: 37507485 DOI: 10.1007/s00280-023-04571-2.


HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.

Esfahani S, de Aguiar Ferreira C, Rotile N, Ataeinia B, Krishna S, Catalano O Mol Imaging Biol. 2022; 25(2):353-362.

PMID: 35962301 PMC: 10024929. DOI: 10.1007/s11307-022-01763-9.


Hyperpolarized [1-C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer.

Esfahani S, Callahan C, Rotile N, Heidari P, Mahmood U, Caravan P Mol Imaging Biol. 2022; 24(5):769-779.

PMID: 35467249 PMC: 9588528. DOI: 10.1007/s11307-022-01727-z.


Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.

Ebert K, Haffner I, Zwingenberger G, Keller S, Raimundez E, Geffers R BMC Cancer. 2022; 22(1):254.

PMID: 35264144 PMC: 8908634. DOI: 10.1186/s12885-022-09335-4.


References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Turke A, Zejnullahu K, Wu Y, Song Y, Dias-Santagata D, Lifshits E . Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010; 17(1):77-88. PMC: 2980857. DOI: 10.1016/j.ccr.2009.11.022. View

3.
Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

4.
Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

5.
Motoyama A, Hynes N, Lane H . The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002; 62(11):3151-8. View